Open an account

Sol Gel Technologies

SLGL · NASDAQ

$65.81+$0.83 (+1.28%)TodayMarket closed ·
Prev close $64.98

About SLGL

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 28 full-time employees. The company went IPO on 2018-02-01. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Employees
28
Headquarters
Ness Ziona, Central(HaMerkaz)
Listed
Feb 1, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
sol-gel.com

SLGL key statistics

Market cap
215.46M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
40.74K
Volume
45.19K
Open price
$63.68
High today
$66.98
Low today
$63.68
52 Week high
$97.97
52 Week low
$28.81

Sol Gel Technologies (SLGL) at a glance

As of Oct 20, 2026, Sol Gel Technologies (SLGL) shares are priced at $65.81, giving the company a market cap of 215.46M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $63.68 and $66.98. The current price is 3.3% above the day's low and 1.7% below its high.

Volume so far is 45.19K shares, in line with the average of 40.74K shares a day.

Over the past year Sol Gel Technologies has ranged from $28.81 to $97.97, and now sits 53% of the way up that range.

Sol Gel Technologies met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.13 per share against an estimate of -$2.36.

The average analyst price target is $155.55, 136.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $155.55
Low
$111.10
Now
$65.81
High
$204.75

SLGL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 52.3% on average.

  1. Q4 FY23: reported -$1.70 per share against an estimate of -$1.78
  2. Q1 FY24: reported -$2.30 per share against an estimate of -$1.53
  3. Q2 FY24: reported $0.70 per share against an estimate of -$2.04
  4. Q3 FY24: reported -$0.10 per share against an estimate of -$1.33
  5. Q3 FY25: reported -$2.13 per share against an estimate of -$2.13
  6. Q4 FY25: reported -$1.07 per share against an estimate of $0.3978
  7. Q1 FY26: reported -$1.31 per share against an estimate of -$1.88
  8. Q2 FY26: reported -$1.13 per share against an estimate of -$2.36

SLGL news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Vandana Singh

    Why Is Small Cap Sol-Gel Tech Stock Falling Today?

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Avi Kapoor

    US Stocks Gain, Nasdaq Surges Over 100 Points

  • Avi Kapoor

    Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Similar companies

Companies in the same industry as Sol Gel Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.